Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction

Open access

Abstract

Background: Alzheimer’s disease (AD) is a neurodegenerative disease characterized by Aβ plaques and neurofibrillary tangles. Chronic inflammation and synaptic dysfunction lead to disease progression and cognitive decline. Small extracellular vesicles (sEVs) are implicated in AD progression by facilitating the spread of pathological proteins and inflammatory cytokines. This study investigates synaptic dysfunction and neuroinflammation protein markers in plasma-derived sEVs (PsEVs), their association with Amyloid-β and tau pathologies, and their correlation with AD progression. Methods: A total of 90 [AD = 35, mild cognitive impairment (MCI) = 25, and healthy age-matched controls (AMC) = 30] participants were recruited. PsEVs were isolated using a chemical precipitation method, and their morphology was characterized by transmission electron microscopy. Using nanoparticle tracking analysis, the size and concentration of PsEVs were determined. Antibody-based validation of PsEVs was done using CD63, CD81, TSG101, and L1CAM antibodies. Synaptic dysfunction and neuroinflammation were evaluated with synaptophysin, TNF-α, IL-1β, and GFAP antibodies. AD-specific markers, amyloid-β (1–42), and p-Tau were examined within PsEVs using Western blot and ELISA. Results: Our findings reveal higher concentrations of PsEVs in AD and MCI compared to AMC (p < 0.0001). Amyloid-β (1–42) expression within PsEVs is significantly elevated in MCI and AD compared to AMC. We could also differentiate between the amyloid-β (1–42) expression in AD and MCI. Similarly, PsEVs-derived p-Tau exhibited elevated expression in MCI compared with AMC, which is further increased in AD. Synaptophysin exhibited downregulated expression in PsEVs from MCI to AD (p = 0.047) compared to AMC, whereas IL-1β, TNF-α, and GFAP showed increased expression in MCI and AD compared to AMC. The correlation between the neuropsychological tests and PsEVs-derived proteins (which included markers for synaptic integrity, neuroinflammation, and disease pathology) was also performed in our study. The increased number of PsEVs correlates with disease pathological markers, synaptic dysfunction, and neuroinflammation. Conclusions: Elevated PsEVs, upregulated amyloid-β (1–42), and p-Tau expression show high diagnostic accuracy in AD. The downregulated synaptophysin expression and upregulated neuroinflammatory markers in AD and MCI patients suggest potential synaptic degeneration and neuroinflammation. These findings support the potential of PsEV-associated biomarkers for AD diagnosis and highlight synaptic dysfunction and neuroinflammation in disease progression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-024-03475-z

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Isolation and analysis of PsEVs. The isolated PsEV morphology characterize by transmission electron microscopy from age-matched healthy controls (AMC) (A), mild-cognitive impairment (MCI) patients (B), and Alzheimer’s disease (AD) (C). The size distribution of PsEVs subpopulation (nm) versus the concentration (particle/ml) in AMC (D), individuals with MCI (E), and AD (F). Comparison of the sEVs concentration of AD, MCI, and AMC patients (G). Receiver operating characteristic (ROC) curve of PsEVs concentration in AMC v/s AD (H), AMC v/s MCI (I), and MCI v/s AD (J) (scale bar 100 nm)
Fig. 1 Isolation and analysis of PsEVs. The isolated PsEV morphology characterize by transmission electron microscopy from age-matched healthy controls (AMC) (A), mild-cognitive impairment (MCI) patients (B), and Alzheimer’s disease (AD) (C). The size distribution of PsEVs subpopulation (nm) versus the concentration (particle/ml) in AMC (D), individuals with MCI (E), and AD (F). Comparison of the sEVs concentration of AD, MCI, and AMC patients (G). Receiver operating characteristic (ROC) curve of PsEVs concentration in AMC v/s AD (H), AMC v/s MCI (I), and MCI v/s AD (J) (scale bar 100 nm)CC BY · PubMed Central
Fig. 2 Validation of PsEVs expression analysis of different markers in PsEVs in age-matched controls (AMC), mild cognitive impairment (MCI), and Alzheimer’s disease patients (AD) (A). Densitometric analysis of CD63 (B), densitometric analysis of CD81 (C), densitometric analysis of TSG101 (D), densitometric analysis of L1CAM (E), densitometric analysis of synaptophysin (F), densitometric analysis of GFAP (G), and densitometric analysis of amyloid-β (1–42) oligomer (H). All densitometric values were normalized against β-actin
Fig. 2 Validation of PsEVs expression analysis of different markers in PsEVs in age-matched controls (AMC), mild cognitive impairment (MCI), and Alzheimer’s disease patients (AD) (A). Densitometric analysis of CD63 (B), densitometric analysis of CD81 (C), densitometric analysis of TSG101 (D), densitometric analysis of L1CAM (E), densitometric analysis of synaptophysin (F), densitometric analysis of GFAP (G), and densitometric analysis of amyloid-β (1–42) oligomer (H). All densitometric values were normalized against β-actinCC BY · PubMed Central
Fig. 3 PsEVs derived amyloid-β (1–42), p-Tau, IL-1β, TNF-α, GFAP, and synaptophysin protein concentration was measured. ELISA results in A shows levels of PsEVs amyloid-β (1–42) in AMC, MCI, and AD and receiver operating characteristic (ROC) curve of PsEVs concentration in AMC v/s MCI (B), AMC v/s AD (C), and MCI v/s AD (D). Similarly, p-Tau concentration in AMC, MCI, and AD (E), ROC curve of PsEVs concentration in AMC v/s MCI (F), AMC v/s AD (G), and MCI v/s AD (H). PsEVs derived IL-1β concentration in AMC, MCI and AD (I), ROC curve of PsEVs concentration in AMC v/s MCI (J), AMC v/s AD (K), and MCI v/s AD (L). PsEVs derived TNF-α concentration in AMC, MCI and AD (M), ROC curve of PsEVs concentration in AMC v/s MCI (N), AMC v/s AD (O), and MCI v/s AD (P). Similarly, GFAP concentration in AMC, MCI, and AD (Q), ROC curve of PsEVs concentration in AMC v/s MCI (R), AMC v/s AD (S), and MCI v/s AD (T). For PsEVs-derived synaptophysin concentration in AMC, MCI, and AD (U), ROC curve of PsEVs concentration in AMC v/s MCI (V), AMC v/s AD (W), and MCI v/s AD (X). Abbreviations: AMC, age-matched control; MCI, mild-cognitive impairment patients; AD, Alzheimer’s disease patients; TNF-α, tumor necrosis factor-alpha; GFAP, glial fibrillary acidic protein
Fig. 3 PsEVs derived amyloid-β (1–42), p-Tau, IL-1β, TNF-α, GFAP, and synaptophysin protein concentration was measured. ELISA results in A shows levels of PsEVs amyloid-β (1–42) in AMC, MCI, and AD and receiver operating characteristic (ROC) curve of PsEVs concentration in AMC v/s MCI (B), AMC v/s AD (C), and MCI v/s AD (D). Similarly, p-Tau concentration in AMC, MCI, and AD (E), ROC curve of PsEVs concentration in AMC v/s MCI (F), AMC v/s AD (G), and MCI v/s AD (H). PsEVs derived IL-1β concentration in AMC, MCI and AD (I), ROC curve of PsEVs concentration in AMC v/s MCI (J), AMC v/s AD (K), and MCI v/s AD (L). PsEVs derived TNF-α concentration in AMC, MCI and AD (M), ROC curve of PsEVs concentration in AMC v/s MCI (N), AMC v/s AD (O), and MCI v/s AD (P). Similarly, GFAP concentration in AMC, MCI, and AD (Q), ROC curve of PsEVs concentration in AMC v/s MCI (R), AMC v/s AD (S), and MCI v/s AD (T). For PsEVs-derived synaptophysin concentration in AMC, MCI, and AD (U), ROC curve of PsEVs concentration in AMC v/s MCI (V), AMC v/s AD (W), and MCI v/s AD (X). Abbreviations: AMC, age-matched control; MCI, mild-cognitive impairment patients; AD, Alzheimer’s disease patients; TNF-α, tumor necrosis factor-alpha; GFAP, glial fibrillary acidic proteinCC BY · PubMed Central
Fig. 4 Correlation analysis between PsEVs concentration and PsEVs derived AD pathology markers. The correlation between PsEVs concentration with the amyloid-β (1–42) (A), p-Tau (B), IL-1β (C), TNF-α (D), GFAP (E), and synaptophysin (F). Abbreviations: p-Tau, Phospho-Tau, TNF-α, tumor necrosis factor-alpha; GFAP, glial fibrillary acidic protein. Spearman correlation was used for correlation analysis
Fig. 4 Correlation analysis between PsEVs concentration and PsEVs derived AD pathology markers. The correlation between PsEVs concentration with the amyloid-β (1–42) (A), p-Tau (B), IL-1β (C), TNF-α (D), GFAP (E), and synaptophysin (F). Abbreviations: p-Tau, Phospho-Tau, TNF-α, tumor necrosis factor-alpha; GFAP, glial fibrillary acidic protein. Spearman correlation was used for correlation analysisCC BY · PubMed Central
Fig. 5 Correlation between neuropsychological test (ACE-III and MMSE) and PsEV-derived AD pathology markers. Amyloid-β (1–42) β, p-Tau, IL-1β, TNF-α, GFAP, and synaptophysin protein concentration. A–F Correlation between ACE-III scores and amyloid-β (1–42) (A), pTau (B), IL-1β (C), TNF-α (D), GFAP (E), and synaptophysin (F) protein concentration. G–L A correlation between MMSE Score and amyloid-β (1–42) (G), p-Tau (H), IL-1β (I), TNF-α (J), GFAP (K), and synaptophysin (L) protein concentration. Abbreviations: ACE-III, Addenbrooke Cognitive Examination; MMSE, Mini-Mental State Examination; p-Tau, Phospho-Tau; TNF-α, tumor necrosis factor-alpha; GFAP, glial fibrillary acidic protein. Spearman correlation was used for correlation analysis
Fig. 5 Correlation between neuropsychological test (ACE-III and MMSE) and PsEV-derived AD pathology markers. Amyloid-β (1–42) β, p-Tau, IL-1β, TNF-α, GFAP, and synaptophysin protein concentration. A–F Correlation between ACE-III scores and amyloid-β (1–42) (A), pTau (B), IL-1β (C), TNF-α (D), GFAP (E), and synaptophysin (F) protein concentration. G–L A correlation between MMSE Score and amyloid-β (1–42) (G), p-Tau (H), IL-1β (I), TNF-α (J), GFAP (K), and synaptophysin (L) protein concentration. Abbreviations: ACE-III, Addenbrooke Cognitive Examination; MMSE, Mini-Mental State Examination; p-Tau, Phospho-Tau; TNF-α, tumor necrosis factor-alpha; GFAP, glial fibrillary acidic protein. Spearman correlation was used for correlation analysisCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Research works printed but not linked: 3

  1. Goetzl EJ, Kapogiannis D, Schwartz JB, Lobach IV, Goetzl L, Abner EL, et al. Decreased synaptic proteins in neuronal exosomes of frontotemporal dementia and Alzheimer’s disease. FASEB J. 2016;30(12):4141–8. · DOI · Paper page
  2. Kim KY, Shin KY, Chang KA. GFAP as a potential biomarker for Alzheimer’s disease: a systematic review and meta-analysis. Cells. 2023;12(9):1309. · DOI · Paper page
  3. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):6977. · DOI · Paper page

Cited by

See all 29

Metadata

Authors
Singh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., Chatterjee, P., Nikolajeff, F., & Kumar, S.
Affiliations
  • All India Institute of Medical Sciences (IN)
  • Indian Institute of Technology BHU (IN)
  • Jamia Millia Islamia (IN)
  • Luleå University of Technology (SE)
Corresponding author
Kumar, Saroj
Venue
BMC Medicine
Published
2024-06-20
Volume
22
Issue
1
Pages
254-254
ISSN
1741-7015 (ISSN-L)
OpenAlex
W4399860075
Cited by
28
References
81
Citations by year
2026: 13 · 2025: 14 · 2024: 1
FWCI
3.81
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Council of Scientific and Industrial Research (09/006(0533)/2021-EMR-I)
  • Department of Health Research , INDIA (YSS/2020/000158)
  • Indian Council of Medical Research (2020-1194)
  • Department of Health Research (GIA/2020/000595)
  • Lulea University of Technology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords
Alzheimer's disease, small extracellular vesicles, plasma-derived extracellular vesicles, synaptic dysfunction, neuroinflammation, amyloid-beta, tau phosphorylation, synaptophysin, IL-1β, TNF-α, glial fibrillary acidic protein, mild cognitive impairment, disease progression biomarkers, CD63, CD81, TSG101, L1CAM
MeSH terms
Extracellular Vesicles, Neuroinflammatory Diseases, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Synapses, Biomarkers, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction. https://app.cochat.ai/papers/10.1186/s12916-024-03475-z
The paper
Singh, R., Rai, S., Bharti, P. S., Zehra, S., Gorai, P. K., Modi, G. P., Rani, N., Dev, K., Inampudi, K. K., Y., V. V., Chatterjee, P., Nikolajeff, F., & Kumar, S. (2024). Circulating small extracellular vesicles in Alzheimer’s disease: a case–control study of neuro-inflammation and synaptic dysfunction. BMC Medicine. https://doi.org/10.1186/s12916-024-03475-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.